NCT05265975 2025-06-09
SWATCH
Antengene Corporation
Phase 1/2 Terminated
Clinical Trials
71 trialsNCT02953509 2025-05-29
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 1/2 Terminated
NCT04464798 2025-04-29
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Celgene
Phase 1 Terminated
NCT03492125 2025-04-10
A Study Of The Selective PKC-β Inhibitor MS- 553
MingSight Pharmaceuticals, Inc
Phase 1/2 Terminated
NCT04419389 2025-03-17
R/R
Aprea Therapeutics
Phase 1/2 Terminated
NCT05144009 2025-01-30
LOTIS-9
ADC Therapeutics S.A.
Phase 2 Terminated
NCT02626455 2024-12-11
CHRONOS-4
Bayer
Phase 3 Terminated
NCT04745832 2024-11-04
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc.
Phase 3 Terminated
NCT03783403 2024-09-19
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Celgene
Phase 1 Terminated
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT04790903 2024-07-11
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1 Terminated
NCT02384954 2024-07-03
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Altor BioScience
Phase 1/2 Terminated
NCT04074330 2024-06-14
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
Takeda
Phase 1/2 Terminated
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT04762160 2024-03-25
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Ipsen
Phase 2 Terminated
NCT02031419 2024-01-18
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Celgene
Phase 1 Terminated
NCT04023071 2023-10-26
FT516 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT04245722 2023-10-26
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
Phase 1 Terminated
NCT02957019 2023-10-10
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Philogen S.p.A.
Phase 1/2 Terminated
NCT02204982 2023-09-28
DYNAMO + R
SecuraBio
Phase 3 Terminated
NCT02391545 2023-09-28
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
SecuraBio
Phase 1/2 Terminated
NCT04502706 2023-06-05
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
Gilead Sciences
Phase 1 Terminated
NCT02914938 2023-05-09
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
MEI Pharma, Inc.
Phase 1 Terminated
NCT04045028 2023-04-07
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Genentech, Inc.
Phase 1 Terminated
NCT04236141 2023-03-03
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
Hoffmann-La Roche
Phase 3 Terminated
NCT02703272 2022-12-02
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 3 Terminated
NCT02954406 2022-02-18
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Takeda
Phase 1 Terminated
NCT01510184 2021-12-16
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT03135262 2021-12-07
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1/2 Terminated
NCT03189836 2021-10-11
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Cogent Biosciences, Inc.
Phase 1 Terminated
NCT01549886 2021-10-04
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT01662102 2021-10-04
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01644253 2021-05-20
Phase 1b Safety and Efficacy Study of TRU-016
Aptevo Therapeutics
Phase 1 Terminated
NCT02951156 2020-12-17
Javelin DLBCL
Pfizer
Phase 3 Terminated
NCT02501473 2020-09-09
MK-3475-174
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Terminated
NCT02624986 2020-05-18
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hoffmann-La Roche
Phase 1/2 Terminated
NCT03670888 2020-01-09
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
JHL Biotech, Inc.
Phase 1 Terminated
NCT03670901 2020-01-09
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
JHL Biotech, Inc.
Phase 3 Terminated
NCT02592876 2019-05-17
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT02258529 2019-05-14
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Gilead Sciences
Phase 2 Terminated
NCT01287741 2019-04-12
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Hoffmann-La Roche
Phase 3 Terminated
NCT01283386 2019-03-14
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
Hoffmann-La Roche
Phase 4 Terminated
NCT02855359 2019-03-11
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT01232556 2019-01-08
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Pfizer
Phase 3 Terminated
NCT01980888 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT02044822 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Gilead Sciences
Phase 2 Terminated
NCT01203930 2018-11-16
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Gilead Sciences
Phase 2 Terminated
NCT01732913 2018-11-16
Yosemite
Gilead Sciences
Phase 3 Terminated
NCT01732926 2018-11-16
Bridalveil
Gilead Sciences
Phase 3 Terminated
NCT01925612 2018-06-21
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Seagen Inc.
Phase 2 Terminated